Antineoplastics and immunomodulators 2026-II Immunopreparats content of the active substance rituximab
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Contract Description
Antineoplastics and immunomodulators 2026-II Immunopreparats content of the active substance rituximab
The contents of the ampoule are 100 mg rituximab, 1 780 ampoules per year (dávek); the contents are 500 mg rituximabu, 1 540 ampules per annum (davek); ATC L01FA01
Related Procurement Opportunities
Similar tenders in Pharmaceuticals, Healthcare and Medicine, Chemicals